14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
HLI vs NMR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Nomura Holdings, Inc (NMR) is the stronger overall head-to-head candidate over Houlihan Lokey, Inc. (HLI) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HLI carries a Unified Composite Score of 37.0/100 (SELL) at $137.66 (16.6x Forward P/E, 22.8% operating margin), whereas NMR carries 44.5/100 (HOLD) at $9.34 (12.7x Forward P/E, 25.1% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HLI vs NMR. Trailing 12-month operating profitability (HLI 22.8% vs NMR 25.1%) and valuation multiples (HLI 16.6x vs NMR 12.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Capital Markets value chain with $9.9B market capitalization and 22.8% operating margin.
OpEx & R&D Reinvestment71.2% of Rev ($1.82B)
90D Engineering Disclosures0 Published
NMR Moat ProfileScale & Operating Efficiency Moat
Capital Markets Operator
Competes within the Capital Markets value chain with $28.3B market capitalization and 25.1% operating margin.
OpEx & R&D Reinvestment52.3% of Rev ($7.77B)
90D Engineering Disclosures0 Published
Investor FAQ HLI vs NMR Key Questions & Quantitative Answers
As of Nov 17, 2026, Nomura Holdings, Inc (NMR) is the stronger overall head-to-head candidate over Houlihan Lokey, Inc. (HLI) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HLI carries a Unified Composite Score of 37.0/100 (SELL) at $137.66 (16.6x Forward P/E, 22.8% operating margin), whereas NMR carries 44.5/100 (HOLD) at $9.34 (12.7x Forward P/E, 25.1% operating margin). Technically, HLI sits in a Neutral phase (RSI 48.9, UNCLASSIFIED options structure) and NMR sits in a Neutral phase (RSI 45.5, UNCLASSIFIED options structure).
NMR leads the Growth & Scale pillar: HLI posts +4.8% YoY revenue growth and +0.4% YoY earnings growth on $2.56B TTM revenue (94.0% gross margin, 22.8% operating margin), compared with NMR at +17.9% YoY revenue growth and +13.6% YoY earnings growth on $14.9B TTM revenue (77.4% gross margin, 25.1% operating margin). On trailing 12-month operating scale, HLI generates $2.56B in USD-normalized revenue versus $14.9B for NMR. In operating R&D and SG&A reinvestment, HLI deploys 71.2% of Rev ($1.82B) (0 90-day corporate R&D disclosures) versus 52.3% of Rev ($7.77B) (0 disclosures) for NMR.
NMR screens cheaper on headline valuation multiples. HLI trades at 16.6x Forward P/E, 24.0x Trailing P/E, 6.54x PEG, and 3.9x EV/Revenue (unreported cash flow margin), whereas NMR trades at 12.7x Forward P/E, 11.2x Trailing P/E, 0.81x PEG, and 1.9x EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HLI (17.3% ROE) versus NMR (11.5% ROE) capital efficiency.
In options market volatility and institutional positioning, HLI carries 26.0% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 41% Vol realized risk). By comparison, NMR carries 30.7% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.03β · 29% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.